AstraZeneca Hits Anti-Infective Target With Arrow Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.
You may also be interested in...
Eyeing The Future: AstraZeneca Farms Out Compounds To Ocular Specialist Alcon
Alcon's now-tenuous relationship with Novartis is unlikely to affect the new five-year research agreement with AstraZeneca.
Eyeing The Future: AstraZeneca Farms Out Compounds To Ocular Specialist Alcon
Alcon's now-tenuous relationship with Novartis is unlikely to affect the new five-year research agreement with AstraZeneca.
Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate
Companies plan IND filing for their next novel NS4A antagonist in the first or second quarter of 2008.